We were delighted to speak to Health Tech World recently about the future of cancer diagnostics.
“Hailed as the future of cancer diagnostics, Dxcover is set to revolutionise healthcare by pioneering a new test to diagnose cancer more quickly, simply and cost-effectively than ever before.”
“Liquid biopsy is a hot topic, it’s a cutting-edge technique which holds great promise,” says Dr Baker, chief technology officer of the business.
“Most research focuses on genomic data, the big US companies are focusing on the genetic information from the tumour – but ours is different and looks at the entire signal from the serum. We don’t just look at tumour markers, we look at the human response. That is then teased apart by machine learning.
“There isn’t really another company out there with our approach, and we hold the patents for the diagnosis of all cancers, so no-one can do exactly what we do. Our platform methodology can handle any serum sample, it’s exactly the same analysis, so there’s great potential.”
Read the full article here
